Treatment Approach: Primary vs. Secondary Insomnia in Psychiatric Disorders
Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for both primary insomnia and insomnia secondary to psychiatric disorders, with comparable efficacy in both populations. 1
Core Recommendation
The 2021 American Academy of Sleep Medicine guidelines provide a STRONG recommendation for multicomponent CBT-I as the treatment of chronic insomnia in adults, explicitly including patients with comorbid psychiatric conditions 1. This represents the highest level of evidence available and should guide your treatment approach regardless of whether the insomnia is primary or secondary.
Key Evidence Supporting Unified Treatment Approach
The guideline meta-analyses examined three distinct patient subgroups:
- Patients with insomnia and no comorbidities
- Patients with insomnia and comorbid psychiatric conditions
- Patients with insomnia and comorbid medical conditions
Critically, CBT-I demonstrated clinically significant improvements across all three groups, with moderate quality evidence showing benefits in:
- Remission rates
- Responder rates
- Sleep quality
- Sleep latency
- Wake after sleep onset 1
A well-designed RCT directly tested this question and found no significant three-way interaction between treatment group, time, and insomnia type, meaning CBT-I produced similar benefits for primary insomnia and comorbid insomnia patients across most measures 2. Only one index suggested marginally better response in primary insomnia, while the overall pattern strongly supported equivalent efficacy.
Treatment Algorithm
Step 1: Deliver CBT-I as First-Line Treatment (Both Primary and Secondary)
Implement multicomponent CBT-I consisting of:
- Sleep education about sleep regulation
- Stimulus control instructions
- Sleep restriction therapy
- Cognitive therapy strategies
- Sleep hygiene education
- Relaxation training and counter-arousal methods
- Ongoing sleep diary monitoring
Typical duration: 4-8 sessions delivered by a trained professional 1
For resource-limited settings: Brief Therapy for Insomnia (BTI) receives a CONDITIONAL recommendation, consisting of 1-4 abbreviated sessions emphasizing behavioral components 1
Step 2: Address the Underlying Psychiatric Condition Concurrently
While CBT-I is effective for insomnia even in psychiatric populations, the underlying psychiatric disorder requires simultaneous treatment 3. However, do not delay insomnia treatment waiting for psychiatric symptom resolution, as insomnia often becomes semi-independent and can exacerbate the primary psychiatric condition if left untreated 4.
Step 3: Consider Adjunctive Pharmacotherapy Strategically
When pharmacotherapy is needed:
For comorbid depression:
- Eszopiclone or trazodone (50-150 mg) are preferred options 5
- Sedating antidepressants (mirtazapine, nefazodone, or tricyclics) for mild-to-moderate depression with insomnia 6
For comorbid anxiety disorders:
- Eszopiclone or zolpidem 5
For PTSD:
- Consider prazosin 5
For bipolar manic episodes:
- Second-generation antipsychotics 5
Critical caveat: Benzodiazepines and benzodiazepine-receptor agonists are not first-line treatment despite being commonly prescribed 7. They should serve only as short-term adjuncts to CBT-I, not as monotherapy 3.
Important Clinical Considerations
Contraindications to Sleep Restriction Component
When using sleep restriction therapy as part of CBT-I, exercise caution in:
- Patients in high-risk occupations (heavy machinery operators, drivers)
- Those predisposed to mania/hypomania
- Patients with poorly controlled seizure disorders 1
Expected Side Effects During CBT-I
Warn patients about temporary early-treatment effects that typically resolve by treatment completion:
- Daytime fatigue and sleepiness
- Mood impairment (irritability)
- Cognitive difficulties (attention problems) 1
Why This Unified Approach Works
The evidence suggests that once chronic insomnia develops—whether primary or secondary—it operates through similar perpetuating mechanisms involving conditioned arousal, maladaptive sleep behaviors, and dysfunctional beliefs about sleep 4. These mechanisms respond to CBT-I regardless of the original precipitating cause.
Implementation Gap
Despite strong guideline recommendations, CBT-I remains underutilized in psychiatric settings. A 2026 survey found that 65% of mental health professionals reported CBT-I is not or rarely offered, with 56% correctly identifying it as first-line treatment but 48% incorrectly identifying benzodiazepines as first-line 7. Digital CBT-I platforms offer a scalable solution to improve accessibility 8.
Long-Term Advantages of CBT-I
Unlike pharmacotherapy, CBT-I provides:
- Durable treatment gains without need for ongoing intervention
- Potential reduction in polypharmacy burden
- No risk of drug-related adverse events
- Superior long-term effectiveness compared to medications 1
The bottom line: Stop differentiating treatment approach based on primary versus secondary insomnia. Use CBT-I as first-line treatment in both scenarios, address the psychiatric comorbidity concurrently, and reserve medications for adjunctive short-term use when absolutely necessary.